When looking to find solid stocks with smooth upward momentum, investors can take a look at the 125/250 day adjusted slope indicator. At the time of writing Sage Therapeutics, Inc. (NasdaqGM:SAGE) have a current value of -9.24812. The point of this calculation is to calculate a longer term average adjusted slope value that smooths out large stock price movements by using the average of the timeframe. This indicator is useful in helping find stocks that have been on an even upward trend over the past 6 months to a year.
Investors may be taking a closer look at holdings and trying to decide which way the stock market will lean in the second half of the year. Maybe there are some surprising winners, and the decision needs to be made to either sell for a profit or hold on for further potential gains. Maybe there are some losers that are being held onto with the hope of a rebound. Sometimes investors may get too emotionally attached to certain stocks. Keeping unbiased focus on the market may help provide the portfolio with an added boost. Nobody knows for sure what will transpire over the next few quarters. As earnings reports flow in, investors will be monitoring which companies provide the biggest surprises.
Sage Therapeutics, Inc. (NasdaqGM:SAGE) of the Pharmaceuticals & Biotechnology sector closed the recent session at 160.930000 with a market value of $7545553.
Investor Target Weight
Sage Therapeutics, Inc. (NasdaqGM:SAGE) has a current suggested portfolio rate of 0.02590 (as a decimal) ownership. Target weight is the volatility adjusted recommended position size for a stock in your portfolio. The maximum target weight is 7% for any given stock. The indicator is based off of the 100 day volatility reading and calculates a target weight accordingly. The more recent volatility of a stock, the lower the target weight will be. The 3-month volatility stands at 96.808400 (decimal). This is the normal returns and standard deviation of the stock price over three months annualized.
Drilling down into some additional key near-term indicators we note that the Capex to PPE ratio stands at 0.000000 for Sage Therapeutics, Inc. (NasdaqGM:SAGE). The Capex to PPE ratio shows you how capital intensive a company is. Stocks with an increasing (year over year) ratio may be moving to be more capital intensive and often underperform the market. Higher Capex also often means lower Free Cash Flow (Operating cash flow – Capex) generation and lower dividends as companies don’t have the cash to pay dividends if they are investing more in the business.
Some dedicated market watchers will preach the old adage, nothing ventured nothing gained. Some may adhere to the slow and steady mindset. The correct play for one investor may not be the same for another. Some may choose to be fully invested while others may keep some cash on the sidelines. Active stock market investors may have to find that perfect balance between being too risky or playing it too safe. If the market keeps charging higher in the second half of the year, investors may have to decide whether to take profits, or let it ride.
In addition to Capex to PPE we can look at Cash Flow to Capex. This ration compares a stock’s operating cash flow to its capital expenditure and can identify if a firm can generate enough cash to meet investment needs. Investors are looking for a ratio greater than one, which indicates that the firm can meet that need. Comparing to other firms in the same industry is relevant for this ratio. Sage Therapeutics, Inc. (NasdaqGM:SAGE)’s Cash Flow to Capex stands at .
In looking at some Debt ratios, Sage Therapeutics, Inc. (NasdaqGM:SAGE) has a debt to equity ratio of 0.00000 and a Free Cash Flow to Debt ratio of . This ratio provides insight as to how high the firm’s total debt is compared to its free cash flow generated. In terms of Net Debt to EBIT, that ratio stands at 3.41081. This ratio reveals how easily a company is able to pay interest and capital on its net outstanding debt. The lower the ratio the better as that indicates that the company is able to meet its interest and capital payments. Lastly we’ll take note of the Net Debt to Market Value ratio. Sage Therapeutics, Inc.’s ND to MV current stands at -0.135365. This ratio is calculated as follows: Net debt (Total debt minus Cash ) / Market value of the company.
Investors may be searching high and low in the market to find some bargain stocks to add to the portfolio. Finding those great stocks at cheap prices may take a lot of research and dedication. Many investors will opt to compare stocks in the same industry. This may be a good way to help determine which ones are poised to stand out above the rest. As we move into the second half of the year, all eyes will be watching the major economic reports. If the data continues to impress, the stock market may continue to cruise along without many hiccups. Careful investors will no doubt be combing through specific company data to make sure the fundamentals are in line as well. Following company fundamentals and stock technicals may help create a wider frame of reference to work with.
Near-Term Growth Drilldown
Now we’ll take a look at some key growth data as decimals. One year cash flow growth ratio is calculated on a trailing 12 months basis and is a one year percentage growth of a firm’s cash flow from operations. This number stands at -1.00000 for Sage Therapeutics, Inc. (NasdaqGM:SAGE). The one year Growth EBIT ratio stands at 0.15584 and is a calculation of one year growth in earnings before interest and taxes. The one year EBITDA growth number stands at 0.15460 which is calculated similarly to EBIT Growth with just the addition of amortization.
Taking even a further look we note that the 1 year Free Cash Flow (FCF) Growth is at -1.00000. The one year growth in Net Profit after Tax is 0.10646 and lastly sales growth was .
There are many factors that may influence stock price action. One of the most influential factors is company earnings. Company earnings reports can be extremely important for investors. Earnings reports have the ability to let investors know how well or poorly a company has been performing. Investors may try to capitalize on trading around earnings announcements. This can be a very tricky venture and may be quite risky. Studying stock price movements around earnings reports can sometimes be confusing. Often times a company will post better than expected numbers but the stock will drop in price. On the other side, shares may see a bounce even after disappointing results. Analysts try to project what numbers the company will post, but they may not be accurate for a variety of reasons. Following analyst estimates around earnings reports may be helpful, but it may be wise to proceed with caution if only going on what the analysts are saying.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.